|Bid||88.07 x 1100|
|Ask||88.04 x 1400|
|Day's Range||87.60 - 88.47|
|52 Week Range||72.30 - 94.19|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||15.44|
|Forward Dividend & Yield||2.98 (3.34%)|
|1y Target Est||98.50|
Clover Health's flu shot-monitoring report was praised by Clinton — part of our weekly Health Care Digest roundup.
Novartis AG (NYSE: NVS ) has been on a tear since hitting a year-over-year nadir in June. As the drugmaker rides positive partnerships, drug approvals and trial successes, one analyst is projecting good ...
AG’s recent acquisition streak is pivoting the company toward new treatments that bear little resemblance to traditional drugs. The Swiss company has spent nearly $15 billion in the past year to build its presence in cutting-edge areas of medical research, including gene therapy, or treatments that introduce new DNA into the body, and radiopharmaceuticals, which are drugs that carry radioactive particles to tumors for close-range radiotherapy. ’s ambition to get ahead on innovative therapies that he believes will drive significant future growth.
Novartis AG said on Friday the U.S. Food and Drug Administration expanded the use of its low platelets drug to treat patients with a rare, genetic blood disorder. The drug, Promacta, received the green light as a combination with standard immunosuppressive therapy to treat patients two years and older suffering from treatment-resistant severe aplastic anemia (SAA). SAA is a blood disorder in which a patient's bone marrow fails to produce enough red blood cells, white blood cells and platelets.
Alphabet Inc's life sciences division Verily said on Friday that it was putting on hold one of its oldest and highest-profile projects, a smart contact lens designed to help monitor sugar levels. The project, started in 2014, aimed to help diabetics better manage their blood sugar levels by embedding sensors on a contact lens to monitor the glucose levels in their tears. In a blog update, Verily cited https://blog.verily.com/2018/11/update-on-our-smart-lens-program-with.html insufficient consistency in the correlation between tear glucose and blood glucose concentrations to support the requirements of a medical device.
Bausch + Lomb/International is a wholly owned subsidiary of Bausch Health Companies (BHC). Bausch + Lomb/International generated revenues of $1.1 billion in the third quarter of this year compared to $1.2 billion in the third quarter of 2017, reflecting a ~7% YoY decline. However, Bausch + Lomb/International witnessed ~3% organic revenue growth.
Novartis launched a copy of Johnson & Johnson's (J&J) inflammation-fighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europe's largest healthcare market. Novartis's Sandoz generics unit in May won European approval for Zessly, known generically as infliximab.
Swiss drugmaker Novartis (NOVN.S) is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off. "We're completely committed to the Sandoz business, and we're looking at transforming it and making it as strong as it can be in the global generics business," Novartis spokesman Sreejit Mohan told Reuters. Earlier, Swiss newspaper Tages-Anzeiger reported the Basel-based drugmaker was preparing to split off Sandoz, citing an employee representative as well as participants in a Novartis investor event last week in London.
Swiss drugmaker Novartis is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off. "We're completely committed to the Sandoz business, and we're looking at transforming it and making it as strong as it can be in the global generics business," Novartis spokesman Sreejit Mohan told Reuters.
Swiss drugmaker Novartis is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan ...
Biohaven Pharmaceutical slumped to a three-week low Wednesday after the biotech reported greater-than-expected third-quarter losses.
Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. The NASDAQ and Russell 2000 indices are already in correction territory. More importantly, the Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in October. Hedge […]
Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017, which reflected ~18% YoY (year-over-year) growth. Xyrem’s net revenues over the first nine months of 2018 amounted to $1.0 billion—compared to $874.2 million in the same period in 2017, which reflects 18% YoY growth.
Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.
Ligand (LGND) beats earnings and sales estimates in the third quarter of 2018 and raises full-year guidance for the second straight quarter.
Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. The drug is made by China's Zhejiang Huahai Pharmaceutical Co Ltd. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan. A review was extended to other 'sartan' medicines, including candesartan, irbesartan, losartan, olmesartan and valsartan, after very low levels of a carcinogen was found in losartan made by Hetero Labs in India.
On June 4, the FDA issued a press release announcing regulatory approval for a biosimilar version of Amgen’s (AMGN) Neulasta and Mylan’s (MYL) Fulphilia. On September 20, the European Medicines Agency issued a press release announcing a positive opinion from the Committee for Medicinal Products for Human Use for Fulphila. According to Mylan’s investor presentation, Fulphila is targeting a global market opportunity worth more than $5.0 billion.
The company's development-stage SMA treatment was supposed to knock out the market leader, but now it may be the one at risk of an upset.
The fast-growing company is consolidating into a larger headquarters in Rockville — not far from its current home.
Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.